MARKET

PHAR

PHAR

Pharming Group N.V.
NASDAQ
10.84
0.00
0.00%
Closed 16:00 03/28 EDT
OPEN
10.84
PREV CLOSE
10.84
HIGH
10.84
LOW
10.84
VOLUME
476
TURNOVER
0
52 WEEK HIGH
16.71
52 WEEK LOW
9.70
MARKET CAP
714.55M
P/E (TTM)
-722.6667
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at PHAR last week (0318-0322)?
Weekly Report · 4d ago
Weekly Report: what happened at PHAR last week (0311-0315)?
Weekly Report · 03/18 10:31
Pharming Group’s Strong Performance and Growth Prospects Justify Buy Rating
Analyst Christian Glennie maintained a Buy rating on the stock and has a €2.05 price target. Glennie highlighted the unexpected 10% growth in revenue from Ruconest in 2023. The strong initial performance of the drug Joenja in the U.S. Market.
TipRanks · 03/18 09:05
Pharming reports Q4 results
Seeking Alpha · 03/15 19:36
Pharming Group Price Target Maintained With a $37.00/Share by HC Wainwright & Co.
Dow Jones · 03/14 16:45
Pharming Group’s Strong Financial Performance and Growth Potential Merit Buy Rating
TipRanks · 03/14 15:35
Earnings Scheduled For March 14, 2024
Pharming is projected to report earnings for its fourth quarter. Dick's Sporting Goods is expected to report quarterly earnings at $3.35 per share on revenue of $817.48 million. Other companies expected to release earnings before the bell include Hello Gr, Weibo and Build-A-Bear Workshop.
Benzinga · 03/14 09:52
Pharming Group Expects 2024 Total Revenue Of $280M-$295M
For 2024, the Company anticipates: Total revenues between US$280 million and US$295 million (14% to 20% growth) Progress towards regulatory approvals for leniolisib in key global markets. Continued focus on potential acquisitions and in-licensing of clinical stage opportunities in rare diseases.
Benzinga · 03/14 06:10
More
About PHAR
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.

Webull offers Pharming Group N.V. stock information, including NASDAQ: PHAR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PHAR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PHAR stock methods without spending real money on the virtual paper trading platform.